Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
THE TWELVE-MONTH CLINICAL FOLLOW-UP RESULTS FOR LARGE ANNULUS PATIENTS OF LuX-Valve Plus EU TRINITY STUDY PRESENTED AT EuroPCR 2026, DEMONSTRATING LARGE SIZE ADVANTAGES WITH PRODUCT

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated data in relation to the latest business and product portfolio development of the Group.

The board ("**Board**") of directors ("**Directors**") of the Company is pleased to announce that recently, the twelve-month clinical follow-up results for large annulus patients (LAP) of the global multi-center clinical trial of the LuX-Valve Plus transcatheter tricuspid valve replacement ("**EU TRINITY**") study were released at EuroPCR 2026, demonstrating its large size advantages, which are expected to address a broad range of unmet clinical needs.

LuX-Valve Plus EU TRINITY STUDY: TWELVE-MONTH FOLLOW-UP RESULTS FOR LAP

– Presented by Prof. Thomas Modine, CHU de Bordeaux-Haut-Leveque, France

EU TRINITY study is a global prospective, multi-center, single-arm clinical trial, which primarily evaluates the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation ("**TR**") and high surgical risk. The study enrolled a total of 161 patients from 20 centers around the world (FAS + Roll-in), among which, 18 centers were from France, Germany, Spain, Denmark, and the United Kingdom.

Patients with severe tricuspid regurgitation often have concomitant dilation of right ventricular and tricuspid annulus, which is one of the primary factors increasing the difficulty of tricuspid regurgitation intervention therapy. For LAP, there are very few safe and effective clinical treatment options, indicating a significant unmet clinical need. LuX-Valve Plus has seven valve sizes ranging from 40mm to 70mm. In the EU TRINITY study, over 75% of patients used valve sizes of 55mm, 60mm, 65mm, and 70mm. The average age of these patients was 77 and the average Tri-Score was as high as 13.6%; 9.7% of patients exhibited Severe TR, 47.8% exhibited Massive TR, and 42.5% exhibited Torrential TR.

The twelve-month clinical follow-up results show the excellent efficacy and safety of LuX-Valve Plus in LAP.

The efficacy results showed:

(1) In terms of improvement in the tricuspid regurgitation grade, 97.8% of LAP[a] showed no above moderate regurgitation;

(2) In terms of New York Heart Association cardiac function improvement, 91.6% of LAP had their postoperative cardiac function improved to class I/II; and

(3) In terms of quality of life, the Kansas City Cardiomyopathy Questionnaire scores improved, on average, by approximately 17 points; in addition, the average improvement in 6-minute walking distance for LAP was approximately 43 meters.

Note a: LAP is defined as patients using valve sizes of 55mm, 60mm, 65mm and 70mm.

The safety results showed:

Clinical Event Committee (CEC) – Adjudicated Composite Events at Twelve-Month	**FAS LAP (N=113)**
Cardiovascular mortality	6.2% (7)
Myocardial infarction	0
Strokes	2.7% (3)
New onset renal failure	1.8% (2)
Severe bleeding (includes fatal, life-threatening and extensive bleeding as defined by MVARC)	8% (9)
Non-selective tricuspid valve surgery/intervention post procedure	5.3% (6)
Major cardiac structural complications	1.8% (2)
Major access site and vascular complications	0
Device-related pulmonary embolism	0
New pacemaker implantation due to AV block	9.7% (11)
Composite Events Rate	28.3%

Although baseline data of patients with large annulus revealed more severe preoperative conditions in terms of tricuspid regurgitation grade, high surgical risk grade, right ventricular function, right atrial volume and degree of tricuspid annular dilatation, as well as more complex anatomical structures, the 12-month clinical follow-up outcomes of large annulus patients in the EU TRINITY study demonstrated that LuX-Valve Plus delivers sustained and excellent safety and efficacy when applied to such patients. Significant improvements were observed in tricuspid regurgitation grade; right cardiac remodeling led to continuous enhancement of cardiac function and marked elevation in quality of life, while maintaining a low incidence rate of composite adverse events.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop and market LuX-Valve Plus. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, 21 May 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.